[In vivo expression of human tissue-plasminogen activator transfected AGZY83-a cells implanted in mice].
OBJECTIVE
To detect the expressing levels of human tissue-plasminogen activator(t-PA) in AGZY83-a cells transfected with pcDNA3.1(+) t-PA in vivo and the feasibility of using transplantation of cells for gene therapy of thrombotic diseases.


METHODS
Expression vectors containing the t-PA cDNA gene were transfected into AGZY83-a cells. The transfected AGZY83-a cells were implanted into mice in different regions, and the plasma levels of human t-PA were assayed at intervals.


RESULTS
The plasma levels of human t-PA were significantly increased in mice after implantation of transfected AGZY83-a cells and were significantly higher than those of control groups implanted with untransfected AGZY83-a cells. This significant increase lasted at least 105 days. The intraperitoneal implantation group expressed the highest level of human t-PA, a little higher than that of the subcutis implantation group, while both are much higher than that of the quadriceps femoris implantation group which expressed the lowest.


CONCLUSIONS
The implanted transfected AGZY83-a cells are able to stably express high levels of human t-PA, and transplantation of cells transfected with pcDNA3.1(+) t-PA is a new promising method for gene therapy of thrombotic diseases.
Zhao
Yongbo
Y
Department of Neurology, Shanghai First People's Hospital, Shanghai 200080 P. R. China. zyb62@hotmail.com
Wang
Feng
F
Li
Yu
Y
Zhang
Ying
Y
Zhang
Guiyin
G
D000818:Animals; D002460:Cell Line; D017690:Cell Transplantation / Q000379:methods*; D015870:Gene Expression; D006801:Humans; D051379:Mice; D010957:Plasmids / Q000235:genetics; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000097:blood / Q000235:genetics*; D014162:Transfection; D014183:Transplantation, Heterologous
D010959:Tissue Plasminogen Activator